Focused On-demand Library for Interleukin-37

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9NZH6

UPID:
IL37_HUMAN

ALTERNATIVE NAMES:
FIL1 zeta; IL-1X; Interleukin-1 family member 7; Interleukin-1 homolog 4; Interleukin-1 zeta; Interleukin-1-related protein

ALTERNATIVE UPACC:
Q9NZH6; B5BU97; Q56AP9; Q8TD04; Q8TD05; Q9HBF2; Q9HBF3; Q9UHA6

BACKGROUND:
Interleukin-37, also referred to as Interleukin-1 family member 7, serves as a critical immune regulatory cytokine. It uniquely suppresses pro-inflammatory cytokine production while sparing anti-inflammatory cytokines, highlighting its selective regulatory function. This protein's ability to inhibit dendritic cell activation further underscores its importance in immune response modulation.

THERAPEUTIC SIGNIFICANCE:
The involvement of Interleukin-37 in inflammatory bowel disease 31, autosomal recessive, underscores its therapeutic potential. By curbing excessive inflammation, targeting Interleukin-37 pathways offers a promising avenue for developing treatments for not only inflammatory bowel diseases but potentially other inflammation-related conditions as well.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.